|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WASHC1 |
Gene summary for WASHC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WASHC1 | Gene ID | 100287171 |
| Gene name | WASH complex subunit 1 | |
| Gene Alias | FAM39E | |
| Cytomap | 9p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A8K0Z3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100287171 | WASHC1 | CCI_2 | Human | Cervix | CC | 2.66e-04 | 5.40e-01 | 0.5249 |
| 100287171 | WASHC1 | CCI_3 | Human | Cervix | CC | 2.52e-08 | 4.45e-01 | 0.516 |
| 100287171 | WASHC1 | CCII_1 | Human | Cervix | CC | 3.96e-04 | 2.74e-01 | 0.3249 |
| 100287171 | WASHC1 | Tumor | Human | Cervix | CC | 4.00e-05 | -1.24e-01 | 0.1241 |
| 100287171 | WASHC1 | LZE4T | Human | Esophagus | ESCC | 8.35e-06 | 1.93e-01 | 0.0811 |
| 100287171 | WASHC1 | LZE5T | Human | Esophagus | ESCC | 1.54e-04 | 2.80e-01 | 0.0514 |
| 100287171 | WASHC1 | LZE7T | Human | Esophagus | ESCC | 2.68e-16 | 5.21e-01 | 0.0667 |
| 100287171 | WASHC1 | LZE8T | Human | Esophagus | ESCC | 3.19e-08 | 2.55e-01 | 0.067 |
| 100287171 | WASHC1 | LZE20T | Human | Esophagus | ESCC | 8.11e-14 | 3.32e-01 | 0.0662 |
| 100287171 | WASHC1 | LZE21D1 | Human | Esophagus | HGIN | 2.75e-06 | 4.56e-01 | 0.0632 |
| 100287171 | WASHC1 | LZE22D1 | Human | Esophagus | HGIN | 4.30e-07 | 2.56e-01 | 0.0595 |
| 100287171 | WASHC1 | LZE22T | Human | Esophagus | ESCC | 1.15e-08 | 5.85e-01 | 0.068 |
| 100287171 | WASHC1 | LZE24T | Human | Esophagus | ESCC | 2.64e-17 | 3.85e-01 | 0.0596 |
| 100287171 | WASHC1 | LZE21T | Human | Esophagus | ESCC | 1.37e-06 | 3.66e-01 | 0.0655 |
| 100287171 | WASHC1 | LZE6T | Human | Esophagus | ESCC | 1.55e-08 | 2.96e-01 | 0.0845 |
| 100287171 | WASHC1 | NAFLD1 | Human | Liver | NAFLD | 1.36e-03 | 4.05e-01 | -0.04 |
| 100287171 | WASHC1 | S014 | Human | Liver | HCC | 5.95e-27 | 8.16e-01 | 0.2254 |
| 100287171 | WASHC1 | S015 | Human | Liver | HCC | 9.95e-28 | 1.12e+00 | 0.2375 |
| 100287171 | WASHC1 | S016 | Human | Liver | HCC | 1.68e-26 | 8.44e-01 | 0.2243 |
| 100287171 | WASHC1 | S027 | Human | Liver | HCC | 5.72e-19 | 1.14e+00 | 0.2446 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
| GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
| GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
| GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
| GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
| GO:003227110 | Cervix | CC | regulation of protein polymerization | 57/2311 | 233/18723 | 2.37e-07 | 1.03e-05 | 57 |
| GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
| GO:003133410 | Cervix | CC | positive regulation of protein-containing complex assembly | 55/2311 | 237/18723 | 2.25e-06 | 6.73e-05 | 55 |
| GO:190290510 | Cervix | CC | positive regulation of supramolecular fiber organization | 50/2311 | 209/18723 | 2.55e-06 | 7.54e-05 | 50 |
| GO:005134810 | Cervix | CC | negative regulation of transferase activity | 60/2311 | 268/18723 | 2.77e-06 | 8.02e-05 | 60 |
| GO:004593610 | Cervix | CC | negative regulation of phosphate metabolic process | 88/2311 | 441/18723 | 2.92e-06 | 8.27e-05 | 88 |
| GO:001056310 | Cervix | CC | negative regulation of phosphorus metabolic process | 88/2311 | 442/18723 | 3.21e-06 | 8.77e-05 | 88 |
| GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:004232610 | Cervix | CC | negative regulation of phosphorylation | 77/2311 | 385/18723 | 1.09e-05 | 2.38e-04 | 77 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WASHC1 | SNV | Missense_Mutation | novel | c.1069G>A | p.Asp357Asn | p.D357N | A8K0Z3 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| WASHC1 | SNV | Missense_Mutation | rs762714703 | c.805G>A | p.Gly269Ser | p.G269S | A8K0Z3 | protein_coding | tolerated(0.54) | possibly_damaging(0.734) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WASHC1 | SNV | Missense_Mutation | novel | c.678G>T | p.Gln226His | p.Q226H | A8K0Z3 | protein_coding | deleterious(0.03) | possibly_damaging(0.549) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WASHC1 | SNV | Missense_Mutation | novel | c.1069N>A | p.Asp357Asn | p.D357N | A8K0Z3 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| WASHC1 | SNV | Missense_Mutation | rs746128171 | c.1076N>A | p.Ser359Tyr | p.S359Y | A8K0Z3 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-KP-A3W0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WASHC1 | SNV | Missense_Mutation | novel | c.572N>A | p.Pro191His | p.P191H | A8K0Z3 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
| WASHC1 | SNV | Missense_Mutation | novel | c.703N>T | p.Val235Leu | p.V235L | A8K0Z3 | protein_coding | deleterious(0.05) | benign(0.289) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| WASHC1 | SNV | Missense_Mutation | novel | c.739N>A | p.Pro247Thr | p.P247T | A8K0Z3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CV-A6K2-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| WASHC1 | SNV | Missense_Mutation | rs761521000 | c.1384N>A | p.Asp462Asn | p.D462N | A8K0Z3 | protein_coding | deleterious(0) | possibly_damaging(0.454) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |